About this file

This is an amendment to solicitation HT9402-25-Q-9201 issued by the Defense Health Agency on February 19, 2025. The amendment removes one specific pharmaceutical agent, Kisqali Femara Co-Pack (a breast cancer agent in the CDKI subclass), from the Class Review Request for Quotation. The removal was initiated by POD (Pharmacy Operations Division) on February 14, 2025.

The original solicitation is part of the DoD Pharmacy Uniform Formulary program and involves a review of multiple breast cancer agents and targeted immunomodulatory biologics for potential inclusion in the DoD Uniform Formulary. The amendment is signed by Contracting Officer Marsha L. Petersen and maintains all other original terms and conditions of the solicitation.

View the file

Other files

File Type Posted
May 2025 PT Meeting Reporting.xlsx XLSX spreadsheet
NDC Price List - Breast Cancer - CDKI.xlsx XLSX spreadsheet
RFQ HT9402-25-Q-9201 CR.pdf PDF
NDC Price List FAQ Class Review.pdf PDF
NDC Price List - TIBS - IL-1 IL-6 CTLA-4.xlsx XLSX spreadsheet

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

DEFENSE HEALTH AGENCY

7700 ARLINGTON BOULEVARD, SUITE 5101

FALLS CHURCH, VIRGINIA 22042-5101

HT9402-25-Q-9201 0001

February 19, 2025

SUBJECT: Amendment to Solicitation HT9402-25-Q-9201 to remove agent from Class Review solicitation.

1. The purpose of this amendment is to remove the agent Kisqali Femara Co-Pack from the Class Review RFQ.

2. On February 14, 2025, POD reached out to Contracting to inform that the following agent is removed from the solicitation:

Kisqali Femara Co-Pack – Breast Cancer Agent – Subclass: CDKI

3. All other terms and conditions remain the same.

Marsha L. Petersen Contracting Officer

2025-02-25T09:12:39-0600
PETERSEN.MARSHA.LISA.1021485299

File details come from the government source that posted it. Updated .